Scott Werner, PA
Pain Medicine · Farr West, UTNPI 1043299357
Payments from drug & device makers
What this record shows
This record is dominated by other: $2,945 of the $4,758 with a category attached, or 61.9%. International Rehabilitative Sciences, Inc accounts for 62.3% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2024 at $3,430 and has fallen 94.5% since, to $187 in 2025.
Across 66 payments — averaging $72.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- International Rehabilitative Sciences, Inc$3K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$420
- Collegium Pharmaceutical, Inc.$364
- Averitas Pharma Inc.$182
- Pfizer$169
- Biodelivery Sciences International, Inc.$126
- plus $531 from 11 others
What the payments were for
- Food & beverage$1,81338%
- Other$2,94562%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| International Rehabilitative Sciences, Inc | 2 | $2,966 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $420 |
| Collegium Pharmaceutical, Inc. | 16 | $364 |
| Averitas Pharma Inc. | 4 | $182 |
| Pfizer | 5 | $169 |
| Biodelivery Sciences International, Inc. | 5 | $126 |
| Indivior Inc. | 5 | $111 |
| GRT US Holding, Inc. | 2 | $90 |
| Tonix Medicines, Inc. | 1 | $84 |
| Redhill Biopharma Inc. | 1 | $71 |
| AbbVie | 2 | $55 |
| Azurity Pharmaceuticals, Inc. | 2 | $34 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $26 |
| Baudax Bio Inc. | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Almatica Pharma LLC | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,758 in reported general payments places this provider in the 60th percentile of 61 pain medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 38 | $40,619 |
| OxycontinOxycodone Hcl | 48 | $23,927 |
| Oxycodone Hcl | 636 | $18,926 |
| Oxymorphone Hcl ErOxymorphone Hcl | 24 | $15,651 |
| Morphine Sulfate ErMorphine Sulfate | 539 | $14,541 |
| Hysingla ErHydrocodone Bitartrate | 15 | $12,029 |
| Fentanyl | 61 | $11,314 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 235 | $8,934 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 28 | $7,948 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 231 | $6,574 |
| Hydromorphone ErHydromorphone Hcl | 15 | $5,998 |
| Dronabinol | 17 | $5,922 |
| Gabapentin | 224 | $2,877 |
| Testosterone | 13 | $2,119 |
| Buprenorphine Hcl | 51 | $2,024 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er | $364 | $40,61938 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 61 pain medicine providers in Utah.
Other pain medicine in Farr West
- Maria SchwartzSalt Lake City$813K
- Jeremy JoyalDraper$170K
- Lynn WebsterSalt Lake City$160K
- Benjamin HumpherysLayton$120K
- Derek HaightDraper$78K
- Jon ObraySt George$24K
- Jason BeckstrandWest Jordan$17K
- Austin AlbrightSalt Lake City$14K
- Jeffrey PenceWest Valley City$13K
- Braden WebbDraper$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.